ApoB versus non-HDL-C: what to do when they disagree.
نویسندگان
چکیده
The high correlation between apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C) is the chief argument employed against introducing apoB into clinical practice. However, high correlation does mean that non-HDL-C and apoB will often yield similar clinical information. Nevertheless, the critical issue is not how often the two tests agree, but how often, and how substantially, they differ. In other words, how often would an apoB result change a clinical decision based on a value for non-HDL-C? This article presents a series of examples from prominent published studies in which apoB and non-HDL-C differ so dramatically that diagnosis and therapy would truly differ depending on which index was used by the physician. These examples establish that apoB and non-HDL-C are not clinical equivalents.
منابع مشابه
Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS).
The results from the clinical trials of LDL lowering with statins could not be clearer or more compelling, and yet the treatment recommendations they have produced could not be more complex or recondite. On the one hand, the densely interwoven skein of pathophysiological, epidemiological, and clinical trial evidence tying LDL to arterial disease and arterial disease to clinical events makes the...
متن کاملNon-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: alternatives and surrogates versus the real thing.
D yslipidemia in patients with diabetes has suddenly emerged as a vital clinical issue. Whereas better glucose control has not been shown to significantly reduce vascular mortality and morbidity (1), lowering LDL cholesterol has regularly been associated with substantial benefit. This may be just the beginning; fibrate therapy also holds promise (2). The Adult Treatment Panel III (ATPIII) reaff...
متن کاملNon-high-density Lipoprotein Cholesterol versus Apolipoprotein B as Predictors for Coronary Heart Disease
Recently non high density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apoB) have been found to be better and more reliable markers of atherosclerotic risk than LDL-C (low density lipoprotein cholesterol).Very few studies, as of now, are available in India which compared their predictability as a cardiovascular risk marker. The aim of our study was to evaluate and compare apoB and ...
متن کاملNon-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math.
With the emergence of new lipid risk markers and a growing cardiometabolic risk burden in the United States, there is a need to better integrate residual risk into cardiovascular disease (CVD) risk stratification. In anticipation of the Adult Treatment Panel IV (ATP IV) guidelines from the National Cholesterol Education Program (NCEP), there exists controversy regarding the comparative performa...
متن کاملAlirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
BACKGROUND Non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low-density lipoprotein cholesterol alone. US and European lipid management guidelines support non-HDL-C and apoB as targets for lipid-lowering therapy. METHODS AND RESULTS This analysis evaluated the efficacy of alirocumab, a pro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Current atherosclerosis reports
دوره 11 5 شماره
صفحات -
تاریخ انتشار 2009